Part,  Chapter, Paragraph

  1   II,     5.  1.  1    | cardio-vascular diseases.~ ~· Multiple Sclerosis~Multiple Sclerosis is a
  2   II,     5.  1.  1    |            Multiple Sclerosis~Multiple Sclerosis is a complex multifactorial
  3   II,     5.  5.  3    |               Downs Syndrome, tuberous sclerosis and Fragile X Syndrome,
  4   II,     5.  5.  3    |                       5.5.3.5 Multiple sclerosis~ ~
  5   II,     5.  5.  3    |                Introduction~ ~Multiple sclerosis (MS) is a chronic progressive
  6   II,     5.  5.  3    |            follow. The Danish Multiple Sclerosis Registry (DMSR) has collected
  7   II,     5.  5.  3    |         European Database for Multiple Sclerosis (EDMUS) has been available
  8   II,     5.  5.  3    |          Concerted Action for Multiple Sclerosis funded by the European Commission (
  9   II,     5.  5.  3    |            Norwegian National Multiple Sclerosis Registry was established
 10   II,     5.  5.  3    |              at the Norwegian Multiple Sclerosis National Competence Centre,
 11   II,     5.  5.  3    |                 Prevalence of Multiple Sclerosis in selected EUGLOREH Countries~ ~
 12   II,     5.  5.  3    |               per 100 000) of Multiple Sclerosis in selected EUGLOREH Contries
 13   II,     5.  5.  3    |               per 100 000) of Multiple Sclerosis in selected EUGLOREH Countries,
 14   II,     5.  5.  3    |              100 000/year) of Multiple Sclerosis in Europe~ ~ ~Systematic
 15   II,     5.  5.  3    |                 Proportion of Multiple Sclerosis patients by disease course
 16   II,     5.  5.  3    |                 Proportion of Multiple Sclerosis patients by disease severity (
 17   II,     5.  5.  3    |              EU citizens with multiple sclerosis has not yet been analysed;
 18   II,     5.  5.  3    |         however, the onset of multiple sclerosis often occurs at the prime
 19   II,     5.  5.  3    |           towards people with multiple sclerosis within the European Union)
 20   II,     5.  5.  3    |           British person with Multiple Sclerosis, Louise McVay. This report
 21   II,     5.  5.  3    |               by the European Multiple Sclerosis Platform and all EU Multiple
 22   II,     5.  5.  3    |           Platform and all EU Multiple Sclerosis Societies. Health Departments
 23   II,     5.  5.  3    |             the management of Multiple Sclerosis;~· A shared agenda in MS
 24   II,     5.  5.  3    |             Good Practice” on Multiple Sclerosis and its reference documents.
 25   II,     5.  5.  3    |               European Map of Multiple Sclerosis, (ww g)~The European Map
 26   II,     5.  5.  3    |              MS patients. The multiple sclerosis therapy consensus group (
 27   II,     5.  5.  3    |               for People with Multiple Sclerosis in Europe by the European
 28   II,     5.  5.  3    |               by the European Multiple Sclerosis Platform and RIMS, Rehabilitation
 29   II,     5.  5.  3    |             Rehabilitation in Multiple Sclerosis (Battaglia et al, 2004).~
 30   II,     5.  5.  3    |           foremost experts in Multiple Sclerosis Rehabilitation in Europe;
 31   II,     5.  5.  3    |        severely affected with multiple sclerosis ( Haffenden et al, 2006).~
 32   II,     5.  5.  3    |       constitute the European Multiple Sclerosis Platform (EMSP). EMSP is
 33   II,     5.  5.  3    |      international level, the Multiple Sclerosis International Federation (
 34   II,     5.  5.  3(26)|                to people with multiple sclerosis within the European Union~
 35   II,     5.  5.  3    |               entitled MS-ID (Multiple SclerosisInformation Dividend)
 36   II,     5.  5.  3    |          citizens affected by Multiple Sclerosis (MS). It will create a standardised
 37   II,     5.  5.  3    |               epidemiology of multiple sclerosis in Europe; good practice
 38   II,     5.  5.  3    |              2004): Report of multiple sclerosis centers. Cephalalgia Hungarica
 39   II,     5.  5.  3    |              for Persons with Multiple Sclerosis in Europe~Baumhackl U, Eibl
 40   II,     5.  5.  3    |                 Prevalence of multiple sclerosis in Austria. Results of a
 41   II,     5.  5.  3    |       Epidemiologic survey of multiple sclerosis in Mures County, Romania.
 42   II,     5.  5.  3    |             The prevalence of multiple sclerosis, distribution of clinical
 43   II,     5.  5.  3    |          history of untreated multiple sclerosis in Iceland. A total population-based
 44   II,     5.  5.  3    |               L et al (1998): Multiple sclerosis in Móstoles, central Spain.
 45   II,     5.  5.  3    |              2004): Report of multiple sclerosis center in Lodz. Cephalalgia
 46   II,     5.  5.  3    |               Epidemiology of multiple sclerosis in Russia and other of the
 47   II,     5.  5.  3    |              Boiko AN (1994): Multiple sclerosis prevalence in Russia and
 48   II,     5.  5.  3    |                Lauer K (eds): Multiple Sclerosis in Europe: An Epidemiological
 49   II,     5.  5.  3    |              of patients with multiple sclerosis in Denmark: a nationwide,
 50   II,     5.  5.  3    |          Damish patients with multiple sclerosis. Brain 127:844-850.~Brønnum-Hansen
 51   II,     5.  5.  3    |             Vandvik B (2001): Multiple sclerosis in Oslo, Norway: prevalence
 52   II,     5.  5.  3    |         European database for multiple sclerosis. J Neurol Neurosurg Psychiatr
 53   II,     5.  5.  3    |      Establishment and use of multiple sclerosis registersEDMUS. Ann Neurol
 54   II,     5.  5.  3    |              of disability in multiple sclerosis. N Engl J Med 343:1430–1438.~
 55   II,     5.  5.  3    |    irreversible disability in multiple sclerosis: an amnesic process. Brain
 56   II,     5.  5.  3    |             Midgard R (2004): Multiple sclerosis in Nord-Trøndelag County,
 57   II,     5.  5.  3    |             The prevalence of multiple sclerosis in the District of Santarem,
 58   II,     5.  5.  3    |                 et al (2002): Multiple sclerosis in Malta in 1999: an update.
 59   II,     5.  5.  3    |            Natural history of multiple sclerosis. In: Compston A (ed). McAlpine 60   II,     5.  5.  3    |               ed). McAlpine’s Multiple Sclerosis, 3rd edition. New York:
 61   II,     5.  5.  3    |     Environmental factors and multiple sclerosis. Lancet 7;268-277.~Ekestern
 62   II,     5.  5.  3    |                Mortality from multiple sclerosis in Austria 19702001: dynamics,
 63   II,     5.  5.  3    |                  Diagnosis of multiple sclerosis: comparison of the Poser
 64   II,     5.  5.  3    |               K (eds) (1994): Multiple Sclerosis in Europe: An Epidemiological
 65   II,     5.  5.  3    |               and Research in Multiple Sclerosis. Prague, Czech Republic
 66   II,     5.  5.  3    |             The prevalence of multiple sclerosis in Tayside, Scotland: do
 67   II,     5.  5.  3    |             The prevalence of multiple sclerosis in the Leeds Health Authority.
 68   II,     5.  5.  3    |              and mortality of multiple sclerosis in Leeds. J Neurol 249:260-
 69   II,     5.  5.  3    |        Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 65:
 70   II,     5.  5.  3    |                 et al (1996): Multiple sclerosis in Italy. A reappraisal
 71   II,     5.  5.  3    |              the incidence of multiple sclerosis in Hordaland County, Norway.
 72   II,     5.  5.  3    |                 et al (2000): Multiple sclerosis in North Norway, and first
 73   II,     5.  5.  3    |        severely affected with multiple sclerosis. [On-line publication available
 74   II,     5.  5.  3    |              of the number of multiple sclerosis patients in germany]. Nervenartz
 75   II,     5.  5.  3    |      Symptomatic Treatment of Multiple Sclerosis. Multiple Sclerosis Therapy
 76   II,     5.  5.  3    |           Multiple Sclerosis. Multiple Sclerosis Therapy Consensus Group (
 77   II,     5.  5.  3    |                 of the German Multiple Sclerosis Society. Eur Neurol. 2006;
 78   II,     5.  5.  3    |              2004): Report of multiple sclerosis center at Charles University.
 79   II,     5.  5.  3    |               Epidemiology of multiple sclerosis in Czechoslovakia. In: Battaglia
 80   II,     5.  5.  3    |                  An Update on Multiple Sclerosis. Monduzzi Editore, Bologna,
 81   II,     5.  5.  3    |               Epidemiology of multiple sclerosis: incidence and prevalence
 82   II,     5.  5.  3    |           based on the Danish Multiple Sclerosis Registry. Acta Neurol Scand
 83   II,     5.  5.  3    |                  Incidence of multiple sclerosis in Denmark 1948-1982: a
 84   II,     5.  5.  3    |             1999): The Danish Multiple Sclerosis Registry: a 50-year follow-up.
 85   II,     5.  5.  3    |             2001). The Danish Multiple Sclerosis Registry. History, data
 86   II,     5.  5.  3    |              investigation of multiple sclerosis in Slovenia. In: Firnhaber
 87   II,     5.  5.  3    |                Lauer K (eds): Multiple Sclerosis in Europe: An Epidemiological
 88   II,     5.  5.  3    |             1988): Fatigue in multiple sclerosis. Arch Neurol 45:435-437.~
 89   II,     5.  5.  3    |    neurological impairment in multiple sclerosis and expanded disability
 90   II,     5.  5.  3    |              disproportion of multiple sclerosis in Czechoslovakia from the
 91   II,     5.  5.  3    |                Lauer K (eds): Multiple Sclerosis in Europe: An Epidemiological
 92   II,     5.  5.  3    |            clinical course of multiple sclerosis: results from an international
 93   II,     5.  5.  3    |              survey. National Multiple Sclerosis Society (USA): Advisory
 94   II,     5.  5.  3    |              on New Agents in Multiple Sclerosis. Neurology 46:907-911.~Lucchinetti
 95   II,     5.  5.  3    |          Distinct patterns of multiple sclerosis pathology indicates heterogeneity
 96   II,     5.  5.  3    |       diagnostic criteria for multiple sclerosis: guidelines from the International
 97   II,     5.  5.  3    |              the Diagnosis of Multiple Sclerosis. Annals of Neurology 50:
 98   II,     5.  5.  3    |        epidemiologic study of multiple sclerosis in Northern Ireland. Neurology
 99   II,     5.  5.  3    |           primary progressive multiple sclerosis in Northern Ireland, UK.
100   II,     5.  5.  3    |               and handicap in multiple sclerosis: a population-based study.
101   II,     5.  5.  3    |             the prevalence of multiple sclerosis in Ireland, an effect of
102   II,     5.  5.  3    |                Dean G (1991): Multiple sclerosis in Cyprus. J Neurol Sci
103   II,     5.  5.  3    |                 Prevalence of multiple sclerosis in Bulgaria. Neuroepidemiology
104   II,     5.  5.  3    |               the person with multiple sclerosis. In: Compston A. (ed). McAlpine’
105   II,     5.  5.  3    |               ed). McAlpine’s Multiple sclerosis. China: Churchill Livingston
106   II,     5.  5.  3    |              and incidence of multiple sclerosis: an epidemiological study
107   II,     5.  5.  3    |                Lauer K (eds): Multiple Sclerosis in Europe: An Epidemiological
108   II,     5.  5.  3    |                 Prevalence of multiple sclerosis in the province of Teruel,
109   II,     5.  5.  3    |                  Incidence of multiple sclerosis in Dijon, France : a population-based
110   II,     5.  5.  3    |               156-159.~MSTCG (Multiple sclerosis therapy consensus group)
111   II,     5.  5.  3    |   immunomodulatory therapy of multiple sclerosis. Update. Nervenarzt 77:1506-
112   II,     5.  5.  3    |                German)~MSTCG (Multiple sclerosis therapy consensus group) (
113   II,     5.  5.  3    |                 The Norwegian Multiple Sclerosis National Competence Centre
114   II,     5.  5.  3    |           Centre and National Multiple Sclerosis registry—a resource for
115   II,     5.  5.  3    |              and incidence of multiple sclerosis in Catania, Sicily. Neurology
116   II,     5.  5.  3    |        Weinshenker BG (2000): Multiple sclerosis. N Engl J Med 343;938-952.~
117   II,     5.  5.  3    |             high frequency of multiple sclerosis in Croatia and Slovenia.
118   II,     5.  5.  3    |       Epidemiological data of multiple sclerosis in the province of Evros,
119   II,     5.  5.  3    |       diagnostic criteria for multiple sclerosis: guidelines for research
120   II,     5.  5.  3    |       Increasing incidence of multiple sclerosis in South Lower Saxony, Germany.
121   II,     5.  5.  3    |               Epidemiology of multiple sclerosis in the region of Szczecin:
122   II,     5.  5.  3    |    Epidemiological aspects of multiple sclerosis: a comparative study of
123   II,     5.  5.  3    |               G et al (2001): Multiple sclerosis epidemiology in Sardinia:
124   II,     5.  5.  3    |       Increasing incidence of multiple sclerosis in the province of Sassari,
125   II,     5.  5.  3    |               epidemiology of multiple sclerosis in Europe. Eur J Neurol
126   II,     5.  5.  3    |               Epidemiology of multiple sclerosis. In: Raine CS, McFarland
127   II,     5.  5.  3    |             Hohlfeld H (eds). Multiple sclerosis. A comprehensive text. Elsevier,
128   II,     5.  5.  3    |       Increasing frequency of multiple sclerosis in Padova, Italy: a 30-year
129   II,     5.  5.  3    |          Compston DAS (1995): multiple sclerosis in the North Cambridgeshire
130   II,     5.  5.  3    |         clinical diagnosis of multiple sclerosis. Neurology 26:20-22.~Rothwell
131   II,     5.  5.  3    |             and prevalence of multiple sclerosis in South East Scotland:
132   II,     5.  5.  3    |               Epidemiology of multiple sclerosis: a critical overview. Can
133   II,     5.  5.  3    |                 Occurrence of multiple sclerosis in central Finland: a regional
134   II,     5.  5.  3    |              the incidence of multiple sclerosis in Finland 1979-1993. Neuroepidemiology
135   II,     5.  5.  3    |      Increasing prevalence of multiple sclerosis in Finland. Acta Neurol
136   II,     5.  5.  3    |            Wikström J (2003): Multiple sclerosis in Finland: incidence trends
137   II,     5.  5.  3    |                 Prevalence of multiple sclerosis in Västerbotten County in
138   II,     5.  5.  3    |         prevalence (1997): of multiple sclerosis in Västerbotten County in
139   II,     5.  5.  3    |            characteristics of multiple sclerosis in Västerbotten County in
140   II,     5.  5.  3    |                 Prevalence of multiple sclerosis in Valladolid, northern
141   II,     5.  5.  3    |                 Prevalence of multiple sclerosis in the L’Aquila district,
142   II,     5.  5.  3    |                the lesions of multiple sclerosis. N Engl J Med 338:278-285.~
143   II,     5.  5.  3    |   International Federation of Multiple Sclerosis) [on line publication available
144   II,     5.  5.  3    |                 Prevalence of multiple sclerosis in Flanders, Belgium. Neuroepidemiology
145   II,     5.  5.  3    |             the prevalence of multiple sclerosis in French farmers. J Neurol
146   II,     5.  5.  3    |    epidemiological studies on multiple sclerosis. Neuroepidemiology 22:65-
147   II,     5.  5.  3    |           Clinically Definite Multiple Sclerosis~CPMS~Clinically Probable
148   II,     5.  5.  3    |           Clinically Probable Multiple Sclerosis~CP-MS~Chronic Progressive
149   II,     5.  5.  3    |           Chronic Progressive Multiple Sclerosis~CNS~Central Nervous System~
150   II,     5.  5.  3    |             Years~DMSR~Danish Multiple Sclerosis Registry~EDSS~Expanded Disability
151   II,     5.  5.  3    |          Agency~EMSP~European Multiple Sclerosis Platform~EU~European Union~
152   II,     5.  5.  3    | Laboratory-Supported Definite Multiple Sclerosis~LSPMS~Laboratory-Supported
153   II,     5.  5.  3    | Laboratory-Supported Probable Multiple Sclerosis~MRI~Magnetic Resonance Imaging~
154   II,     5.  5.  3    |          Resonance Imaging~MS~Multiple Sclerosis~MS-ID~Multiple Sclerosis
155   II,     5.  5.  3    |               Sclerosis~MS-ID~Multiple Sclerosis Information Dividend~MSIF~
156   II,     5.  5.  3    |     Information Dividend~MSIF~Multiple Sclerosis International Federation~
157   II,     5.  5.  3    |              Federation~MSTCG~Multiple Sclerosis Therapy Consensus Group~
158   II,     5.  5.  3    |           Primary Progressive Multiple Sclerosis~PR-MS~Progressive-Relapsing
159   II,     5.  5.  3    |         Progressive-Relapsing Multiple Sclerosis~RR-MS~Relapsing-Remitting
160   II,     5.  5.  3    |           Relapsing-Remitting Multiple Sclerosis~SC~Subcutaneously~SP-MS~
161   II,     5.  5.  3    |         Secondary Progressive Multiple Sclerosis~UK~United Kingdom~WHO~World
162   II,     5.  6.  3    |       osteophytes and subchondral bone sclerosis) and thickening of the capsule.
163   II,     5.  6.  3    |          changes (loss of joint space, sclerosis and osteophytes) that have
164   IV,    13.  2.  2    |                total DALY for Multiple Sclerosis in Europe is 307 000 years
165  Key,   Ap5.  0.  0    |             school~schools~scleroderma~sclerosis~sedentariness~seizure~seizures~